| MASL vs. MASH |
NAS <4 (0) vs. NAS ≥4 (1) |
2776 |
3132 |
0.9: 1 |
| At-Risk MASH |
NAS <4 AND/OR F<2 (0) vs. NAS ≥4 AND F≥2 (1) |
4014 |
2010 |
2.0: 1 |
| High Activity |
A <2 (0) vs. A ≥2 (1) |
2426 |
3672 |
0.7: 1 |
| Clinically Significant Fibrosis |
F <2 (0) vs. F ≥2 (1) |
3771 |
2532 |
1.5: 1 |
| Advanced Fibrosis (Histology confirmed) |
F <3 (0) vs. F ≥3 (1) |
4921 |
1382 |
3.6: 1 |
| Cirrhosis (Histology confirmed) |
F <4(0) vs. F ≥4 (1) |
5815 |
488 |
11.1: 1 |
| Advanced Fibrosis (Histology & Clinically confirmed) |
F <3 (0) vs. F ≥3 AND clinically cirrhotic cases (1) |
5163 |
1510 |
3.4: 1 |
| Cirrhosis (Histology & Clinically confirmed) |
F <4 (0) vs. F ≥4 AND clinically cirrhotic cases (1) |
6009 |
664 |
9.0: 1 |
| At-Risk MASLD |
Otherwise (0) vs. 2 ≥ F ≥ 3 AND NAS ≥4 (1) (Cirrhotics Excluded) |
3979 |
1406 |
2.8: 1 |
